ViiV Culture=Backstabbing

Discussion in 'GlaxoSmithKline' started by anonymous, Aug 6, 2018 at 12:04 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    ViiV was a good place once. Good luck and share opportunity to keep positive in helping.
     

  2. anonymous

    anonymous Guest

    Sorry to hear that, would have hoped things would be better for this part of the organization. Will be interesting to see where Waterhouse and Eric take it.
     
  3. anonymous

    anonymous Guest

    News Flash To Management:

    Juluca sucks, nobody is using this crap, or ever will. We are getting KILLED out here.
     
  4. anonymous

    anonymous Guest

    Several years ago right after the launch of Triumeq, on a teleconference or at some meeting, I can’t remember which, Marlon stated how many touches Gilead gets with each Dr. per month compared with us. Said we had to get to X amount of touches.

    I knew that was the beginning of the end bc we were going to start measuring success by how many calls are made on a dr. (Nevermind how many are actually made by Viiv or Gilead). Then they made the RAM s territories smaller and it was damn near impossible for us to do that stupid thing where we had to work with counterparts to put the semesters call plan in place.

    I fortunately got an offer elsewhere shortly after that. Viiv was a great place to work with some great people, I’ve got a lot of friends there. Best of luck to everyone.
     
  5. anonymous

    anonymous Guest

    Touches don’t matter if the quality of your product is inferior to competitors
     
  6. anonymous

    anonymous Guest

    R U serious? ViiV always sucked, from day one! It was formed from the residue of dying organizations! The team was made up of dinosaur dingle berries not able to compete for better jobs. They deluded themselves by telling themselves “patients first” and “i work for the patient”. So many LOOSERS!

     
  7. anonymous

    anonymous Guest

    Bill, Marlon, and Colleen were GSK trainees totally ill-equiped for competing with the big powers in the HIV market place, they should have stayed with vacines and consumer marketing. Demanding that reps visit clinics so frequently and having mangers looking over their shoulders was a moronic plan - here we are facing a big down sizing and locked out of most clinics. But when they implemented those stupid plans they were all at the end of their careers so they were just throwing shit at the wall hoping to get a few more bucks toward their retirements or departures, not caring about doing what was right- well done jerks. But corp america rewards that type of stupidity. Enjoy the rewards of your ineptitude and its ripple effect.

    And then the managers - most of them were brought over from the GSK kindergarten and acted like dumb specialty trainees. I have been horrified by what I have witnessed with these bafoons. ViiV is never going to be a mover and a shaker in HIV care, we are just being trounced by Gilead. Day late and a dollor short. You’ve erned my 15 hours a week of work. Twits.
     
  8. anonymous

    anonymous Guest

    No surprise. From the senior sales/marketing, product managers, and down to the RSD level we have a GSK reach and frequency model from the 90s which is no surprise since all of leadership came from GSK. The fact we waste time on measuring edetail use to influence FCRs and year end ratings says it all. Bill, Marlon, and Colleen were wise to get while the gettings good.
     
  9. anonymous

    anonymous Guest

    To boot more GSK folks will be hired into the senior sales leadership positions. I would put money on Eric hiring a GSK person for the Area VP position and also for the SVP position. One would think.... OK so the GSK has not preformed well over the past years... Why bring those people over to ViiV. But this is the world we live in. These people think the ViiV people that have been here for a while are useless.
     
  10. anonymous

    anonymous Guest

    Our new products suck, marketing sucks, lack of numbers and true sales mentality suck, Gilead is absolutely kicking our ass in every facet of the HIV game from products to programs to marketing, and now we get to look forward to layoffs.
     
  11. anonymous

    anonymous Guest

    Lol. My RSD is obsessed with eDetail and RF more than sales. I can get a 5 that way.
     
  12. anonymous

    anonymous Guest

    Wow! You must have to do 2 calls/ day instead of 1! The horror
     
  13. anonymous

    anonymous Guest

    your ass should have been fired like the rest of those GSK primary care hacks.
     
  14. anonymous

    anonymous Guest

    I’ve never seem hemorrhaging like I’m seeing in my territory from Triumeq, and almost none of it is going to Juluca. Scary times here.
     
  15. anonymous

    anonymous Guest

    Point of Denver meeting was to train so RSDs can have more made up fake coaching reasons in C2W. Anyone who came over from GSK knows that deal. Gotta love the mandatory reinforcement calls today. My docs don’t believe DTG/3TC will do anwith initial therapy indication and giving market to Biktarvy by blowing off Triumeq and giving DTG/Descovy away. Being optimistic that we have enoughpipeline to not layoff
     
  16. anonymous

    anonymous Guest

    Customers are already calling DTG/3TC “Juluca light”. I don’t think there could be a worse launch than Juluca, but this could be it. Better price next years 2 drug dog at 1/2 the current prices and hope we can fool MHC into forcing patients on it.
     
  17. anonymous

    anonymous Guest

    Actually I think DTG/3TC launch will be far worse as we are going after initial and switch. The expectation will be bigger and the customers don’t want 2DR. I bet we ignore Triumeq again. So much for listening to the market. Sigh.
     
  18. anonymous

    anonymous Guest

    true - so do we price it really cheap, like we should and try to force customers to use this 2 drug crap via MHC? Problem is, if we do than we expose Triumeq and it’s price even greater than it already is. Quite the pickle, and in neither case do we, the salesforce, benefit. I’m starting to see why layoffs are being discussed......
     
  19. anonymous

    anonymous Guest

     
  20. anonymous

    anonymous Guest

    HIV is formulary controlled just like any other primary care med. Did you read UHC. ViiV is primary care pods.